CelSiege Biosciences

CelSiege Biosciences is a biotechnology company specializing in the development of a novel "Cell-in-Cell" (CiC) platform for the treatment of solid tumors. Their proprietary technology acts as a "Trojan Horse," utilizing carrier cells to protect and deliver therapeutic effector cells, such as NK cells or CAR-T cells, directly into the immunosuppressive tumor microenvironment. By overcoming the physical and chemical barriers of solid tumors, CelSiege aims to enhance the efficacy and infiltration of cell therapies. The company is currently in the pre-clinical stage, focusing on optimizing its delivery system for various oncology indications.